Ignite Creation Date:
2024-05-06 @ 1:37 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04077255
Status:
RECRUITING
Last Update Posted:
2022-11-30
First Post:
2019-08-28
Brief Title:
EGFR-targeted Therapy for Gastric Cancer
Sponsor:
National Cancer Center Korea
Organization:
National Cancer Center Korea
Study Overview
Official Title:
Anti-EGFR Antibody GC-1118 in Combination With Weekly Paclitaxel as a Second-line Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas With Amplifications
Status:
RECRUITING
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Based on targeted NGS panel results metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody GC-1118 in combination with weekly paclitaxel as a second-line therapy
Detailed Description:
Participants will receive each treatment if the gastric cancer tissue sample reveals either EGFR gene amplification or strong 3 or 2 EGFR immunostaining
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None